05-03-2025
US FDA expands use of allergic reaction nasal spray in people between 15-30 kilograms
March 5 (Reuters) - The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' (SPRY.O), opens new tab nasal spray for severe allergic reactions in patients who weigh between 15 and 30 kilograms, the company said on Wednesday.
Shares of the company were up 4.5% in extended trading.
The spray, sold under the brand name neffy, will be dosed at 1 milligram (mg) for the new patient population, compared to the previously approved dose of 2 mg for people who weigh above 30 kilograms.
Neffy, which was first approved by the FDA in August, is seen as an alternative to EpiPen and other autoinjectors that are filled with epinephrine.
It is designed to be given at the first sign of a severe allergic reaction to prevent life-threatening conditions such as anaphylaxis.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
